Skip to main content
SpringerLink
Log in

Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma

  • Original Article
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

In vivo demonstration of hypoxia is of significance for tumour patient management. Fluorine-18 fluoromisonidazole ([18F]FMISO) is a proven hypoxie imaging agent. We developed an [18F]FMISO tumour to muscle retention ratio (TMRR) for the detection of tumour hypoxia in nasopharyngeal carcinoma (NPC). Data were acquired by positron emission tomography (PET) of the nasopharynx and neck after intravenous injection of 370 MBq of [18F]FMISO. Two imaging protocols were adopted: a long protocol for comprehensive dynamic information and a short protocol for a simple, clinically convenient imaging procedure. Tomograms were reconstructed and evaluated visually. ROI analysis on the basis of time-activity curve evaluation was performed to calculate the TMRR of NPC or cervical nodal metastases (CNMs) in relation to the suboccipital muscles at 2 h. The calculation of the TMRR was exactly the same for both the long and the short protocol as two 30-min composite frames had been created immediately after intravenous injection and 2 h after injection of [18F]FMISO in the long protocol. The normal tissue to muscle retention ratio (NTMRR) was derived similarly from the normal nasopharynx. The data of 12 controls and 24 patients with NPC were analysed. The long protocol was used in 15 patients, and the short protocol in nine. In controls, the mean NTMRR±1 SD was 0.96±0.14. The mean TMRRs for NPC and CNMs were 2.56±1.50 and 1.35±0.51, respectively; these values were significantly higher than the mean NTMRR for normal controls (P<0.005 in each case). At the retention threshold value of 1.24, tumour hypoxia occurred in 100% of the primary lesions of NPC and 58% of CNMs. The TMRR for undifferentiated carcinoma was significantly lower than that for non-keratinized carcinoma (P<0.05). The [18F]FMISO TMRR is a simple and clinically useful index for detecting tumour hypoxia in NPC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mottram JC. Factors of importance in the radiosensitivity of tumors.Br J Radiol 1936; 9: 606–614.

    Google Scholar 

  2. Powers WE, Tolmach LJ. A multi-component x-ray survival curve for mouse lymphosarcoma cells irradiated in vivo.Nature 1963; 197: 710–711.

    Google Scholar 

  3. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis and a survey of existing data.Int J Radiat Oncol Biol Phys 1984; 10: 695–712.

    PubMed  Google Scholar 

  4. Gatenby RA, Kessler HB, Rosenblum SJ, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy.Int J Radiat Oncol Biol Phys 1988; 14: 831–838.

    PubMed  Google Scholar 

  5. Cater DB, Silver LA. Quantitative measurements of oxygen tension in normal tissues and in the tumors of patients before and after radiotherapy.Acta Radiol 1960; 53: 233–256.

    PubMed  Google Scholar 

  6. Hockel M, Knoop C, Schlenger K, et al. Intratumoral PO2 histography as predictive assay in advanced cancer of the uterine cervix. In: Vaupel P et al., eds.Oxygen transport to tissue XV. New York: Plenum Press; 1994: 445–450.

    Google Scholar 

  7. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia: review article.Eur J Nucl Med 1995; 22: 265–280.

    PubMed  Google Scholar 

  8. Webster LT. Drugs used in chemotherapy of protozoal infections. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds.The pharmacological basis of therapeutics, 8th edn. New York: Pergamon Press; 1990; 1002–1004.

    Google Scholar 

  9. Edwards DI. Nitroimidazole drugs — action and resistance mechanisms. I. Mechanisms of action.J Antimicrob Chemother 1993; 31: 9–20.

    Google Scholar 

  10. Brown JM. Hypoxic cell radiosensitisers: Where next?Int J Radiat Oncol Biol Phys 1989; 16: 987–993.

    PubMed  Google Scholar 

  11. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability.Br J Cancer 1981; 43: 546–550.

    PubMed  Google Scholar 

  12. Martin GV, Caldwell JH, Rasey JS, Grunbaum Z, Cerqueira M, Krohn KA. Enhanced binding of the hypoxic cell marker [18F]fluoromisonidazole in ischemic myocardium.J Nucl Med 1989; 30: 194–201.

    PubMed  Google Scholar 

  13. Rasey JS, Grunbaum Z, Magee S, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells.Radiat Res 1987; 111: 292–304.

    PubMed  Google Scholar 

  14. Rasey JS, Koh W, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as in imaging agent for tumor hypoxia.Int J Radiat Oncol Biol Phys 1989; 17: 985–991.

    PubMed  Google Scholar 

  15. Grierson JR, Link JM, Mathis CA, Rasey IS, Krohn KA. A radiosynthesis of fluorine-18 fluoromisonidazole.J Nucl Med 1989; 30: 343–350.

    PubMed  Google Scholar 

  16. Grunbaum Z, Freauff SJ, Krohn KA, et al. Synthesis and characterization of congeners of misonidazole for imaging hypoxia.J Nucl Med 1987; 28: 68–75.

    PubMed  Google Scholar 

  17. Rasey JS, Grunbaum Z, Shankland EG, et al. Imaging tumor hypoxia with [F-18]fluoromisonidazole [abstract]. J Nucl Med 1987; 28: 594.

    Google Scholar 

  18. Rasey JS, Nelson NJ, Chin L, et al. Characterization of the binding of labeled fluoromisonidazole in cells in vitro.Radiat Res 1990; 122: 301–308.

    PubMed  Google Scholar 

  19. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.Int J Radiat Oncol Biol Phys 1991; 22: 199–212.

    Google Scholar 

  20. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with fluorine-l8-fluoromisonidazole.J Nucl Med 1992; 33: 2133–2137.

    PubMed  Google Scholar 

  21. American Joint Committee on Cancer Manual for Staging Cancer, 4th edn. Philadelphia: J.B. Lippincott; 1992; 37.

  22. Cherif A, Yang DJ, Tansey W, et al. Rapid synthesis of 3[18F]fluoro-l-(2′-nitro-l′-imidazolyl)-2-propanol [(18F]fluoro-misonidazole).Pharm Res 1994; 11: 466–469.

    PubMed  Google Scholar 

  23. Cater DB. Oxygen tension in neoplastic tissues.Tumori 1964; 50: 435–444.

    PubMed  Google Scholar 

  24. Varghese AJ, Whitmore GF. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity in misonidazole.Cancer Res 1980; 40: 2165–2169.

    PubMed  Google Scholar 

  25. Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ. Synthesis and biodistribution of F-18-labeled fluoronitroimidazoles: potential markers of hypoxic tissue.Appl Radiat Isot 1986; 37: 599–605.

    Google Scholar 

  26. Koh WJ, Rasey JS, Grierson JR, et al. Hypoxia imaging of tumors using [F-18] fluoromisonidazole.J Nucl Med 1989; 30: 789.

    Google Scholar 

  27. Koh WJ, Rasey JS, Evans ML, et al. Imaging human tumor hypoxia using [F-18] fluoromisonidazole.J Nucl Med 1991; 32: 955.

    Google Scholar 

  28. Koh WJ, Rasey JS, Grierson JR, et al. Hypoxia imaging of tumors using [1F-18] fluoromisonidazole [abstract].J Nucl Med 1989; 30: 789.

    Google Scholar 

  29. Chapman JD. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies.Radiother Oncol 1991; 20 Suppl l: 13–19.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine and National PET/Cyclotron Center, Taipei Veterans General Hospital, 11217, Taipei, Taiwan

    Shin-Hwa Yeh, Ren-Shyan Liu, Liang-Chih Wu, Chi-Wei Chang, Tong-Wei Yu & Kou-Liang Chou

  2. Division of Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    David J. Yang

  3. Cancer Center, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taipei, Taiwan

    Sang-Hue Yen & Kuang Y. Chen

Authors
  1. Shin-Hwa Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ren-Shyan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liang-Chih Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David J. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sang-Hue Yen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chi-Wei Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tong-Wei Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kou-Liang Chou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kuang Y. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yeh, SH., Liu, RS., Wu, LC. et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 23, 1378–1383 (1996). https://doi.org/10.1007/BF01367595

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01367595

Key words

Search

Navigation